Evidence shows that the concentration of CD8+ and FOXP3+ Treg TIL in the tumor background can be regarded as predictive markers of the platinum-based neoadjuvant chemotherapy response in patients with advanced NSCLC [103,104]. Here, CD8A is linked to neoplasm.